Apart from the contribution of apoptosis and ABC transporter inhibition to the anticancer effect of 1–3, our studies also showed that these dual-targeting agents significantly inhibited the proliferation of BC cells by blocking cell cycle in the S-phase in a dose-dependent manner. Here, ABCG2 is linked to breast cancer.